Beta Bionics, Inc. (BBNX) Earnings
Beta Bionics, Inc. is expected to report next earnings on October 27, 2026 (in NaN days), with a consensus EPS estimate of $-0.55. BBNX has beaten EPS estimates in 5 of its last 6 reported quarters (average surprise +17.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 29, 2026 | $-0.58 | $-0.53 | +8.8% | $32M | +1.7% |
| Apr 21, 2026 | $-0.53 | $-0.49 | +7.5% | $28M | +2.5% |
| Feb 17, 2026 | $-0.42 | $-0.30 | +28.6% | $32M | +18.5% |
| Oct 28, 2025 | $-0.45 | $-0.33 | +26.7% | $27M | -5.7% |
| Jul 29, 2025 | $-0.51 | $-0.39 | +23.5% | $23M | +6.1% |
| Mar 25, 2025 | $-0.42 | $-1.82 | -333.3% | $20M | +26.6% |
| Dec 31, 2023 | — | $-3.13 | — | $8M | — |
| Sep 30, 2023 | — | $-1.71 | — | $3M | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · July 29, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Product Development and Manufacturing - The Islet system was upgraded to use Gorilla Glass 3 for its screen, reducing screen breakage frequency and lowering warranty expenses, which improved gross margin and delivers a better patient experience. - Progress on the upcoming Mint product launch: 510(k) submission is complete, clean room construction is finished, and semi-automated production lines are fully operational, replacing older manual lines as the launch configuration. Full automation will be added in a future phase. - Mint is designed with a two-part architecture: expensive core components are housed in a reusable two-year unit, while the disposable portion (changed with each insulin refill) has a very low bill of materials. This design is expected to deliver an advantaged gross margin profile relative to competing patch pumps at scale, and the initial semi-automated manufacturing phase is capex-light. Commercial Operations - 20 new sales territories were added via territory splits in the first half of 2026, as most existing reps had large geographies that left many target accounts unvisited. New reps will first secure existing accounts to avoid disruption, then expand coverage to previously unvisited locations. - Beta Bionics was an early adopter of pharmacy channel reimbursement for insulin pumps, and the company has existing contracts and relationships with PBMs and health plans through Islet. This existing infrastructure will significantly speed up coverage approval for Mint post-launch. - Beta Bionics' Islet system is highly differentiated from competing products: it requires less active patient and clinician management of settings, positioning it as an accessible population health tool that serves a different target patient than more manual, intensive competing systems.
Guidance
- Management expects the 2025 growth pattern for new patient starts to hold in 2026. New sales territories added in H1 2026 are expected to become more productive as reps gain tenure, and Q4 is expected to be seasonally stronger than Q3 (though seasonality is muted due to pharmacy channel dynamics). - Management confirmed that Q2 2026 new patient start growth met internal expectations. - Management expresses upgraded confidence in having sufficient manufacturing capacity ready to support Mint's upcoming launch, having hit all required development milestones to date.
Segment performance
No segment-level financial performance data (absolute values or revenue contribution percentages) was provided in the excerpted transcript.
Risks & headwinds
No material risks or operational failures were explicitly discussed in the excerpted transcript.
Analyst Q&A
Q: Analysts asked if new competing insulin pump products with expanded sales forces have made it harder for Beta Bionics to win accounts, and what competitive trends management is seeing. /
A: CEO Sean Saint responded that Beta Bionics has not seen competitors pull target patients away. He noted that competing products target a different segment: they require intensive manual settings adjustment, while Islet is a differentiated, low-management product that serves a broader patient population as a population health tool, and the target patient groups do not meaningfully overlap.\n\nQ: An analyst asked whether the 20 new sales territories were in entirely unrepresented regions, or just territory splits to expand depth of coverage. / A: Saint explained there is almost no fully unrepresented (white space) geography left for Beta Bionics, so all new territories are splits of large existing territories. New reps will first secure existing accounts to avoid disruption, then add coverage of previously unvisited accounts in the split areas, resulting in net new reach. Stephen added all splits were completed in H1 2026.\n\nQ: An analyst asked why warranty expense declined, and whether the decline signals higher patient retention. / A: Stephen explained the main driver of lower warranty expense is an upgrade to Gorilla Glass 3 for Islet's screen, which has drastically reduced screen breakage rates. While happier patients from fewer breaks may improve retention, this secondary impact is hard to measure, but the improved durability directly boosted gross margin.\n\nQ: An analyst asked how the entry of other pump players into the pharmacy reimbursement channel impacts Beta Bionics' PBM discussions. / A: Management noted broader industry adoption of the pharmacy channel makes PBM conversations more routine, as the model becomes more normalized. While this creates some short-run negotiation, it is healthy long-term for Beta Bionics, which prioritizes pharmacy channel reimbursement for both Islet and Mint, and the existing PBM relationships built for Islet will accelerate Mint's coverage approval.\n\nQ: An analyst asked when revenue growth will outpace operating expense growth, and when the company will generate free cash flow. / A: Stephen declined to name a specific revenue threshold or timeline for free cash flow generation, but noted that Beta Bionics' required revenue scale to reach profitability is far lower than typical for diabetes medtech companies, and returning profit to shareholders is a core company principle.